1. Home
  2. FRMM vs ACET Comparison

FRMM vs ACET Comparison

Compare FRMM & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FRMM

Forum Markets Incorporated Common Stock

N/A

Current Price

$5.29

Market Cap

75.7M

Sector

Health Care

ML Signal

N/A

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$8.30

Market Cap

79.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FRMM
ACET
Founded
N/A
1947
Country
United States
United States
Employees
2
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
75.7M
79.9M
IPO Year
2017
2017

Fundamental Metrics

Financial Performance
Metric
FRMM
ACET
Price
$5.29
$8.30
Analyst Decision
Buy
Strong Buy
Analyst Count
1
3
Target Price
$5.00
$48.33
AVG Volume (30 Days)
353.5K
88.6K
Earning Date
05-26-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$183.55
N/A
Revenue Next Year
$166.48
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.76
$0.46
52 Week High
$7.15
$9.47

Technical Indicators

Market Signals
Indicator
FRMM
ACET
Relative Strength Index (RSI) 44.94 48.39
Support Level $4.78 $7.78
Resistance Level $5.60 $8.68
Average True Range (ATR) 0.57 0.49
MACD -0.13 -0.06
Stochastic Oscillator 11.11 32.62

Price Performance

Historical Comparison
FRMM
ACET

About FRMM Forum Markets Incorporated Common Stock

Forum Markets Inc is a financial technology company focused on developing infrastructure that supports the origination, financing, and distribution of RWAs through blockchain-enabled capital markets. The company's business approach is centered on integrating traditional financial asset markets with blockchain-based infrastructure to enable the tokenization of income-generating real-world assets such as consumer credit, equipment finance assets, and other contractual cash-flow streams. It utilizes blockchain infrastructure, including Ethereum and related Layer-2 scaling protocols, to support the issuance, management, and potential secondary trading of tokenized financial instruments.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).

Share on Social Networks: